# reload+after+2024-01-20 01:45:03.309021
address1§Kalvebod Brygge 43
city§Copenhagen
zip§1560
country§Denmark
phone§45 70 20 27 28
website§https://www.genmab.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
fullTimeEmployees§2132
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Jan G.J. van de Winkel Ph.D.', 'age': 62, 'title': 'Co-Founder, President & CEO', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 2759408, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Anthony  Pagano', 'age': 45, 'title': 'Executive VP & CFO', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 1027439, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Anthony  Mancini', 'age': 52, 'title': 'Executive VP & COO', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 1115505, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Martin  Schultz', 'age': 47, 'title': 'Senior Director of Clinical Operations  & Non-Independent Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 73389, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Judith V. Klimovsky M.D.', 'age': 65, 'title': 'Executive VP & Chief Development Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 1159538, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Tahamtan  Ahmadi', 'age': 50, 'title': 'Executive VP, Chief Medical Officer & Head of Experimental Medicines', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 1100828, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mijke  Zachariasse Ph.D.', 'age': 49, 'title': 'Senior Director, Head of Antibody Research Materials & Non-Independent Director', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 146777, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Takahiro  Hamatani', 'age': 48, 'title': 'Senior Director of Finance Japan & Non-Independent Director', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 73389, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Andrew  Carlsen', 'title': 'Senior Director, VP & Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Birgitte  Stephensen M.Sc.', 'age': 62, 'title': 'Executive VP & Chief Legal Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§1
compensationRisk§8
shareHolderRightsRisk§1
overallRisk§3
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.721
priceToSalesTrailing12Months§1.2132591
currency§USD
dateShortInterest§1702598400
forwardEps§15.57
pegRatio§0.19
exchange§NMS
quoteType§EQUITY
shortName§Genmab A/S
longName§Genmab A/S
firstTradeDateEpochUtc§1243863000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§5594dda7-7736-3abc-bcfd-5fa676c317ff
gmtOffSetMilliseconds§-18000000
targetHighPrice§54.0
targetLowPrice§32.0
targetMeanPrice§42.05
targetMedianPrice§45.58
recommendationMean§2.5
recommendationKey§buy
numberOfAnalystOpinions§11
quickRatio§11.357
earningsGrowth§-0.175
grossMargins§0.99413
ebitdaMargins§0.39564
trailingPegRatio§1.423
